Research
Andersson has contributed to the field of pharmacology by developing therapeutic interventions for urinary disorders,particularly benign prostatic hyperplasia,and neurogenic bladder dysfunction,with a focus on novel pharmacological targets and mechanisms. [2] His earlier studies had demonstrated that cGMP-dependent protein kinase I (cGKI) mediates nitric oxide/cGMP-induced smooth muscle relaxation,while cAMP signals independently,as cGKI-deficient smooth muscle still responds to cAMP. [11] Furthermore,looking into the role of neurotransmitters in erectile function,he examined how pharmacological treatments,such as phosphodiesterase inhibitors and prostaglandin E1,help treat erectile dysfunction by promoting smooth muscle relaxation. [12]
Reviewing investigational pharmacological treatments for overactive bladder syndrome and related conditions,Andersson laid emphasis on the limitations of existing therapies in efficacy and tolerability and the need for improved options. [13] With Anders Arner,he analyzed advancements in understanding the properties,contractile system,signaling pathways,and receptors of detrusor smooth muscle,along with its alterations in pathological bladder conditions. [14] His research underscored strategies to treat neurogenic bladder dysfunction after spinal cord injury,focusing on lesion-reducing agents and bladder-targeted interventions for detrusor overactivity and sphincter dyssynergia. [15] Investigating the potential of various drugs,including TRP channel blockers,P2X3 receptor antagonists,and gene therapies,for treating bladder storage dysfunction,he highlighted challenges such as side effects and limited clinical efficacy. [16] Additionally,his work emphasized cinaciguat,a soluble guanylate cyclase (sGC) activator effective under oxidative stress,as a potential improvement over PDE5 inhibitors like tadalafil for treating benign prostatic hyperplasia and bladder outflow obstruction. [17]
This page is based on this
Wikipedia article Text is available under the
CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
